Understanding and Improving ¹⁸F-Fluciclovine PET/CT Reports: A Guide for Physicians Treating Patients with Biochemical Recurrence of Prostate Cancer

Figure 4

Images of a 79-year-old male who had undergone radical prostatectomy, salvage radiation, and proton beam therapy for oligometastases to L3 and multiple lymph nodes. He was referred for ¹⁸F-fluciclovine imaging with PSA rising to 2.03 ng/mL. (a) MIP view, sagittal plane. The black arrow points to enhanced uptake, consistent with metastasis in the proximal left femur. The blue arrow points to the pancreas (normal physiologic uptake). (b) Axial, fused PET/CT image (white arrow) and corresponding CT view (yellow arrow) show a metastasis in the proximal left femur. (c) Of interest, this PET/CT view and the corresponding CT view show a previously-irradiated metastasis in L3; note the absence of ¹⁸F-fluciclovine uptake (white arrow) on PET and presence of sclerosis on CT (yellow arrow).

(a)

(b)

(c)